UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2020
Commission File Number:001-38547
Autolus Therapeutics plc
(Translation of registrant’s name into English)
Forest House
58 Wood Lane
White City
London W12 7RZ
United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
☒ Form20-F ☐ Form40-F
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Other Events
On May 22, 2020, Autolus Therapeutics plc (the “Company”) published its UK Annual Report and Accounts for the15-month period ended December 31, 2019 (the “UK Annual Report”) and distributed a notice of its annual general meeting (“AGM”), a form of proxy and its UK Annual Report to its ordinary shareholders.
The UK Annual Report, AGM Notice and Form of Proxy are furnished herewith as Exhibits 1, 2, and 3, respectively, to this Report on Form6-K.
The information contained in the UK Annual Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.
EXHIBIT LIST
Exhibit | Description | |
1 | Annual Report and Accounts for the15-month period ended December 31, 2019 | |
2 | Notice of Annual General Meeting | |
3 | Form of Proxy |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Autolus Therapeutics plc | ||||||
Date: May 26, 2020 | By: | /s/ Christian Itin | ||||
Name Christian Itin, Ph.D. | ||||||
Title: Chief Executive Officer |